Search

587 Result(s)
Sort by

GioTag Final Data

GioTag Final Data

Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Outside the lab…inside the family

Outside the lab…inside the family

We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.
The impact of A Life in a Day of a patient

The impact of A Life in a Day of a patient

A Life in a Day disease simulations are opening our eyes to the patient experience, exposing a surprising knowledge gap and driving change.
FDA approval NexGard PLUS for dogs

FDA approval NexGard PLUS for dogs

Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Catherine Alonzo

Catherine Alonzo

Catherine Alonzo, Patient Safety Physician, Metabolism, tells us about the importance of drug surveillance.
Our evolved employer value proposition

Our evolved employer value proposition

Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Keep water clean

Keep water clean

Human beings can’t survive without water. Further, the safe production of medicines depends on clean drinking water.
The GPP Charter

The GPP Charter

The GPP Charter defines a collaborative approach to identifying common goals for the GPP community
Award winning employers

Award winning employers

Boehringer Ingelheim focuses on the wellbeing of its employees – and is therefore also a "Global Top Employer 2023".
Netherton syndrome (NS)

Netherton syndrome (NS)

Information on Netherton syndrome (NS), a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.